Development and Evaluation of Sustained Release Tablet Formulations of Venlafaxine Hydrochloride

Basit Öğe Kaydı
dc.contributor.authorSaar, Sinem
dc.contributor.authorYıldız, Ayşegül
dc.contributor.authorÜnal, İlay Sema
dc.contributor.authorÖzdal, Zeliha Duygu
dc.contributor.authorDemiröz, Fatmanur Tuğcu
dc.contributor.authorKodan, Esra
dc.contributor.authorOlğaç, Seval
dc.date.accessioned2023-04-10T20:31:02Z
dc.date.available2023-04-10T20:31:02Z
dc.date.issued2022
dc.departmentRektörlük, Rektörlüğe Bağlı Birimler, Düzce Üniversitesi Dergilerien_US
dc.description.abstractAim: Depression is a mental disorder which affects more than 250 million people independently of their age. Venlafaxine is an antidepressant drug and used also for the treatment of panic attack and anxiety with fewer side effects than older antidepressant therapeutics. However, venlafaxine hydrochloride (VH) has a short half-life which requires three times dosing daily to maintain sufficient plasma drug concentration. The aim of this study is to develop sustained release VH tablets to be given once a day. Material and Methods: Polyethylene oxide, sodium alginate, hydroxypropyl methyl cellulose, guar gum and polyacrylic acid were used as controlled release agent. Tablets were prepared by direct compression method. Powder (angle of repose, flow rate, Carr index and Hausner ratio) and tablet (weight uniformity, hardness, friability,) characterizations were evaluated. In vitro release studies were carried out for 24 h and drug release kinetics were evaluated using different models. Results: All formulations showed suitable Carr index and Hausner ratio except the formulation prepared with guar gum. The tablets which had been manufactured via direct compression method were compared to the commercial tablet. Sustained release of VH was observed for all formulations. Based on the in-vitro dissolution studies, the drug release from F1 formulation which comprising HPMC and Carbopol polymers was found similar as compared to the commercial tablets. Conclusion: Directly compressed VH tablets could be a preferable alternative to the commercial tablets on behalf of patient compliance and fewer manufacturing steps compared to other production methods.en_US
dc.identifier.doi10.33631/sabd.1055227
dc.identifier.endpage35en_US
dc.identifier.issn2792-0542
dc.identifier.issue1en_US
dc.identifier.startpage28en_US
dc.identifier.trdizinid505107en_US
dc.identifier.urihttp://doi.org/10.33631/sabd.1055227
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/505107
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12035
dc.identifier.volume12en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofSağlık Bilimlerinde Değer (Online)
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectvenlafaksin hidroklorüren_US
dc.subjectoral tableten_US
dc.subjectdoğrudan basımen_US
dc.subjectuzatılmış salımen_US
dc.subjectdepresyon tedavisien_US
dc.titleDevelopment and Evaluation of Sustained Release Tablet Formulations of Venlafaxine Hydrochlorideen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12035.pdf
Boyut:
634.48 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Sağlık Bilimlerinde Değer (Online) Koleksiyonu